Matthew Herper covers medical innovation — both its promise and its perils. A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk ... The health services company’s first such play, EncircleRx, has grown since its launch in early 2024 to cover ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/16/25, Eli Lilly (Symbol ... following the ups and downs of company profits over time. Therefore, a good first due diligence ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

For those who have been hesitant to cover ... Lilly's Zepbound would no longer be preferred. Novo Nordisk would not comment on the new pharmacy benefits arrangements. But a spokesperson for Eli ...

In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Eli Lilly, looking at the dividend history chart for ...

(Reuters) -Eli Lilly ... by the company in a press release and presented at the European Congress on Obesity. The results of the head-to-head trial come days after CVS Health's decision to drop ...